For Medical Professionals
Living with ALK+
Our Studies
- eXalt3
- eXalt2
- vorolanib
- About Clinical Trials
- Close
Our Science
About Us

Join a study for ALK+ Lung Cancer

February 7, 2018

Ensartinib in Melanoma Press Release. Please click on the link below for details. You can find more information on this and other Ensartinib trials on the clinicaltrials.gov website.

Xcovery Announces Initiation of Phase 2 Clinical Trial for Ensartinib in Melanoma Patients with ALK Alternations

Ensartinib Effective, Well-Tolerated in Patients With ALK+, TKI-Naive NSCLC Xcovery Announces First Cohort of Patients Dosed in a Phase 1/2 Clinical Trial of Vorolanib in Combination with Nivolumab for Treatment of Non-small Cell Lung Cancer or Thymic Carcinoma

Related Posts

Ensartinib at the 2019 European Lung Cancer Conference

Business Wire Press Release

Ensartinib Effective, Well-Tolerated in Patients With ALK+, TKI-Naive NSCLC

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Comment

Name *

Email *

Website

FOR MORE INFORMATION

OR

CALL 561-835-9356

©2017 XCOVERY ALL RIGHTS RESERVED.

Contact Us
Privacy

YOU ARE LEAVING THE XCOVERY SITE.

XCOVERY IS NOT RESPONSIBLE FOR AND DOES NOT HAVE CONTROL

OR INFLUENCE OVER CONTENT,

ACCURACY OR VIEWS EXPRESSED ON EXTERNAL WEBSITES.

TO RETURN TO XCOVERY.COM (CLICK HERE)

TO LEAVE XCOVERY.COM (CLICK HERE)

YOU ARE LEAVING THE XCOVERY SITE.

XCOVERY IS NOT RESPONSIBLE FOR AND DOES NOT HAVE CONTROL

OR INFLUENCE OVER CONTENT,

ACCURACY OR VIEWS EXPRESSED ON EXTERNAL WEBSITES.

TO RETURN TO XCOVERY.COM (CLICK HERE)

TO LEAVE XCOVERY.COM (CLICK HERE)

YOU ARE LEAVING THE XCOVERY SITE.

XCOVERY IS NOT RESPONSIBLE FOR AND DOES NOT HAVE CONTROL

OR INFLUENCE OVER CONTENT,

ACCURACY OR VIEWS EXPRESSED ON EXTERNAL WEBSITES.

TO RETURN TO XCOVERY.COM (CLICK HERE)

TO LEAVE XCOVERY.COM (CLICK HERE)